<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335322</url>
  </required_header>
  <id_info>
    <org_study_id>NCHECR-ALTAIR</org_study_id>
    <nct_id>NCT00335322</nct_id>
  </id_info>
  <brief_title>ALTAIR - Alternative Antiretroviral Strategies : a Comparison of Three Initial Regimens</brief_title>
  <official_title>A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In treatment naïve HIV infected subjects, combination antiretroviral therapy including
      efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral
      efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with
      tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and
      abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to compare the virological efficacy, as measured by
      the time-weighted mean change from baseline plasma HIV-RNA, and safety, of three strategic
      regimens of initial antiretroviral therapy (ART) containing a fixed dose formulation of
      tenofovir and emtricitabine, with either efavirenz or ritonavir boosted atazanavir or
      zidovudine plus abacavir. (Primary comparisons are regimen I versus II and I versus III as
      described below).

      I. tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV) II. tenofovir (TDF) +
      emtricitabine (FTC) + ritonavir/atazanavir (r/ATV) III. tenofovir (TDF) + emtricitabine (FTC)
      + zidovudine (ZDV) + abacavir (ABC)

      Secondary objectives of this study will be to undertake a range of analyses including but not
      limited to the following,

        1. Percentage of patients &lt; 50 copies HIV RNA/mL (and &lt; 400 copies/mL) at week 48 and week
           96 between treatment arms.

        2. Time to confirmed (first of two consecutive) plasma HIV-1 RNA &lt; 50 copies/mL (and &lt; 400
           copies/mL) between treatment arms.

        3. Time to virologic failure defined as confirmed plasma HIV-1 RNA &gt; 50 copies/mL (and 400
           copies/mL) after confirmed &lt; 50 copies/mL (where time = 0 if patient never achieves
           plasma virus load &lt; 50 or &lt;400 copies/mL).

        4. Mean change from baseline of absolute CD4+ T cell count at weeks 48 and 96 between
           treatment arms.

        5. Time to change in randomly assigned therapy (all reasons individually and on aggregate)
           between treatment arms.

        6. Time to first virologic failure (defined as #3 above) or cessation of randomly assigned
           antiretroviral therapy.

        7. Mean change from baseline Lipodystrophy Case Definition score at weeks 48 and 96 between
           treatment arms.

        8. Mean change from baseline in peripheral and central adipose tissue, as measured by CT
           and DEXA at weeks 48 and 96 between treatment arms.

        9. Mean change from baseline in fasting lipid and glycemic parameters at weeks 48 and 96
           between treatment arms.

       10. Comparison of total number of patients with any serious adverse events (SAEs), and the
           cumulative incidence of SAEs, between treatment arms.

       11. Comparison of total number of patients with any adverse events (AEs), and the cumulative
           incidence of AEs, associated with cessation of randomly assigned therapy between
           treatment arms.

       12. Patterns of genotypic HIV resistance associated with virological treatment failure
           across treatment arms.

       13. Describe aspects of immune reconstitution disease.

       14. Adherence to therapy and associations with virologic outcomes between treatment arms.

       15. Comparison of quality of life between treatment arms.

      Following the result of the scheduled week 48 data analysis, the protocol steering committee
      amended the study protocol as follows:

        -  Patients on Arms I and II will remain on the current study drugs

        -  Patients on Arm III may be switched at the physician's discretion to either Arm I or II

        -  There will be a protocol amendment to include one extra follow up visit at week 144 for
           all patients, regardless of treatment arm or current treatment

        -  All patients are to be encouraged to stay on the study up to week 144, to maximize
           follow up on study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Mean Change From Baseline Plasma HIV-RNA.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the Safety of Three Strategic Regimens of Initial ART Containing a Fixed Dose Formulation of Tenofovir and Emtricitabine, With Either Efavirenz or Ritonavir Boosted Atazanavir or Zidovudine Plus Abacavir.</measure>
    <time_frame>144 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)</intervention_name>
    <description>Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)</intervention_name>
    <description>Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)</intervention_name>
    <description>Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive by licensed diagnostic test with presumed duration of infection &gt; 6
             months from date of randomisation.

          -  Aged &gt; 16 years of age (or minimum age as determined by local regulations or as legal
             requirements dictate).

          -  Antiretroviral treatment naïve.

          -  Qualifying plasma HIV RNA &gt; 2,000 copies/mL and a CD4+ T cell count of ≥ 50 cells/µL.

          -  No evidence of harbouring a drug resistant HIV (based upon genotypic drug testing).

          -  Calculated creatinine clearance (CLCr) greater than or equal to 70 mL/min
             (Cockcroft-Gault formula).

          -  Able to provide written informed consent.

        Exclusion Criteria:

          -  The following laboratory variables,

               -  absolute neutrophil count (ANC) &lt; 750 cells/µL

               -  haemoglobin &lt; 8.0 g/dL

               -  platelet count &lt; 50,000 cells/µL

               -  serum AST, ALT &gt; 5 x upper limit of normal (ULN)

               -  serum bilirubin &gt; 1.5 x ULN

          -  Pregnant or nursing mothers.

          -  Current use of human growth hormone, testosterone or other anabolic steroid.

          -  Current use of any prohibited medications as described in product specific
             information.

          -  Acute therapy for serious infection or other serious medical illness (in the judgement
             of the site Principal Investigator) requiring systemic treatment and/or
             hospitalisation.

          -  Patients with current alcohol or illicit substance use that in the opinion of the site
             Principal Investigator would conflict with any aspect of the conduct of the trial.

          -  Patients unlikely to be able to remain in follow-up for the protocol-defined period.

          -  Patients with known renal insufficiency.

          -  Patients with obstructive liver disease.

          -  Patients with intractable diarrhoea (six loose stools/day for at least seven
             consecutive days).

          -  History of acute or chronic pancreatitis.

          -  Presence of cardiomyopathy (due to any cause) or any significant cardiovascular
             disease, such as unstable ischemic heart disease.

          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Cooper, AO DSc MD FRACP FRCPA FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <results_reference>
    <citation>Puls RL, Srasuebkul P, Petoumenos K, Boesecke C, Duncombe C, Belloso WH, Molina JM, Li L, Avihingsanon A, Gazzard B, Cooper DA, Emery S; Altair Study Group. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis. 2010 Oct 1;51(7):855-64. doi: 10.1086/656363.</citation>
    <PMID>20735258</PMID>
  </results_reference>
  <results_reference>
    <citation>Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA; Altair Study Group. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010 Mar 15;50(6):920-9. doi: 10.1086/650743. Erratum in: Clin Infect Dis. 2010 Sep 1;51(5):638.</citation>
    <PMID>20146627</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2006</study_first_posted>
  <results_first_submitted>April 17, 2012</results_first_submitted>
  <results_first_submitted_qc>April 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2012</results_first_posted>
  <last_update_submitted>April 17, 2012</last_update_submitted>
  <last_update_submitted_qc>April 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus (HIV)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TDF/FTC+EFV</title>
        </group>
        <group group_id="P2">
          <title>TDF/FTC+r/ATV</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)</description>
        </group>
        <group group_id="P3">
          <title>TDF/FTC+AZT+ABC</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomised but withdrew prior to ART sta</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF/FTC+EFV</title>
        </group>
        <group group_id="B2">
          <title>TDF/FTC+r/ATV</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)</description>
        </group>
        <group group_id="B3">
          <title>TDF/FTC+AZT+ABC</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="105"/>
            <count group_id="B4" value="327"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Mean Change From Baseline Plasma HIV-RNA.</title>
        <time_frame>48 weeks</time_frame>
        <population>Modified ITT; all randomised pts who started drug</population>
        <group_list>
          <group group_id="O1">
            <title>TDF/FTC+EFV</title>
          </group>
          <group group_id="O2">
            <title>TDF/FTC+r/ATV</title>
          </group>
          <group group_id="O3">
            <title>TDF/FTC+AZT+ABC</title>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Mean Change From Baseline Plasma HIV-RNA.</title>
          <population>Modified ITT; all randomised pts who started drug</population>
          <units>log copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.59" lower_limit="-2.67" upper_limit="-2.41"/>
                    <measurement group_id="O2" value="-2.69" lower_limit="-2.89" upper_limit="-2.49"/>
                    <measurement group_id="O3" value="-2.39" lower_limit="-2.54" upper_limit="-2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compare the Safety of Three Strategic Regimens of Initial ART Containing a Fixed Dose Formulation of Tenofovir and Emtricitabine, With Either Efavirenz or Ritonavir Boosted Atazanavir or Zidovudine Plus Abacavir.</title>
        <time_frame>144 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TDF/FTC+EFV</title>
        </group>
        <group group_id="E2">
          <title>TDF/FTC+r/ATV</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)</description>
        </group>
        <group group_id="E3">
          <title>TDF/FTC+AZT+ABC</title>
          <description>Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased blood pressure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anemias and marrow depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hematological and lymphoid tissue therapeutic procedures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrhythmias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility and defaecation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General systems disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic and heaptobiliary disroders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Allergic conditions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>infection class unspecified</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Viral infectious disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Therapeutic procedure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations, imaging and histopathology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pleural disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>maternal complications of pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Depressed mood and disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Ovarian and fallopian tube disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disorder NEC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Fatal outcome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vascular hemorrhagic disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Venous varices</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Reduced blood pressure disorders</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="115"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal motility and defaecation disorders</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="105"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Gastrointestinal signs and symptoms</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="105"/>
                <counts group_id="E3" events="68" subjects_affected="68" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Body temperature disorders</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>General systems disorder</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="105"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>heaptic and hepatobiliary disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="105"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic condition</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="105"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Fungal infections</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Infections - pathogennot specified</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="115"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E3" events="32" subjects_affected="32" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Viral infections</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headaches</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="105"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sleep disorders</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory disroder NEC</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal and dermal disorders</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="105"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Inadequate sample size for true comparison of non-inferiority</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sean Emery</name_or_title>
      <organization>Kirby Institute</organization>
      <phone>9385 0900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

